ATE235915T1 - Behandlung von hämorrhagischem virusfieber mit protein c - Google Patents

Behandlung von hämorrhagischem virusfieber mit protein c

Info

Publication number
ATE235915T1
ATE235915T1 AT99965808T AT99965808T ATE235915T1 AT E235915 T1 ATE235915 T1 AT E235915T1 AT 99965808 T AT99965808 T AT 99965808T AT 99965808 T AT99965808 T AT 99965808T AT E235915 T1 ATE235915 T1 AT E235915T1
Authority
AT
Austria
Prior art keywords
protein
treatment
hemorrhagic virus
provides
virus fever
Prior art date
Application number
AT99965808T
Other languages
German (de)
English (en)
Inventor
Charles Jack Fisher
Sau-Chi Betty Yan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE235915T1 publication Critical patent/ATE235915T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99965808T 1998-11-20 1999-11-15 Behandlung von hämorrhagischem virusfieber mit protein c ATE235915T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10915398P 1998-11-20 1998-11-20
PCT/US1999/027074 WO2000030677A1 (en) 1998-11-20 1999-11-15 Method of treating viral hemorrhagic fever

Publications (1)

Publication Number Publication Date
ATE235915T1 true ATE235915T1 (de) 2003-04-15

Family

ID=22326085

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99965808T ATE235915T1 (de) 1998-11-20 1999-11-15 Behandlung von hämorrhagischem virusfieber mit protein c

Country Status (12)

Country Link
US (2) US6270764B1 (https=)
EP (1) EP1131091B1 (https=)
JP (1) JP2002530353A (https=)
CN (1) CN1326356A (https=)
AT (1) ATE235915T1 (https=)
AU (1) AU2149800A (https=)
BR (1) BR9915460A (https=)
CA (1) CA2351470A1 (https=)
DE (1) DE69906568T2 (https=)
ES (1) ES2195655T3 (https=)
IL (1) IL142220A0 (https=)
WO (1) WO2000030677A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2351470A1 (en) * 1998-11-20 2000-06-02 Charles Jack Fisher Method of treating viral hemorrhagic fever
WO2002024215A2 (en) * 2000-09-18 2002-03-28 Eli Lilly And Company Method for using activated protein c for the treatment of coagulation-associated disorders
EA200400548A1 (ru) 2001-10-15 2005-06-30 Чирон Корпорейшн Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
US7132398B2 (en) 2003-05-06 2006-11-07 Dendreon Corporation Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
EP1729791A2 (en) * 2004-03-17 2006-12-13 Chiron Corporation Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)
WO2007092607A2 (en) * 2006-02-09 2007-08-16 Genetech, Inc. Treatment of hemorrhagic viral infections using a tissue factor inhibitor
RU2379034C1 (ru) * 2008-11-17 2010-01-20 Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" Способ лечения геморрагической лихорадки с почечным синдромом
EP3551198B1 (en) * 2016-12-08 2022-02-02 Cellphire Inc. Compositions and methods for treatment of loss of fluids leading to hypotension and/or hypovolemia
CA3121200A1 (en) 2018-11-30 2020-06-04 Cellphire, Inc. Platelets as delivery agents
WO2020112963A1 (en) 2018-11-30 2020-06-04 Cellphire, Inc. Platelets as delivery agents
IL322149A (en) 2019-05-03 2025-09-01 Cellphire Inc Materials and methods for manufacturing blood products
CN114450066A (zh) 2019-08-16 2022-05-06 塞尔菲乐有限公司 作为抗血小板剂逆转剂的血栓小体
CA3170196A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc. Anti-fibrinolytic loaded platelets
TW202245814A (zh) 2021-02-17 2022-12-01 美商賽菲爾公司 用於治療抗血小板誘導的凝血病之凍乾血小板衍生物組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
AT402262B (de) 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
CZ298429B6 (cs) * 1997-04-28 2007-10-03 Eli Lilly And Company Stabilní lyofilizovaný prostredek
CA2351470A1 (en) * 1998-11-20 2000-06-02 Charles Jack Fisher Method of treating viral hemorrhagic fever
EP1090130A1 (en) * 1999-04-30 2001-04-11 Eli Lilly And Company Protein c derivatives

Also Published As

Publication number Publication date
CN1326356A (zh) 2001-12-12
US20010028880A1 (en) 2001-10-11
US6270764B1 (en) 2001-08-07
ES2195655T3 (es) 2003-12-01
US6767539B2 (en) 2004-07-27
EP1131091A1 (en) 2001-09-12
DE69906568T2 (de) 2004-02-12
AU2149800A (en) 2000-06-13
DE69906568D1 (de) 2003-05-08
EP1131091B1 (en) 2003-04-02
WO2000030677A1 (en) 2000-06-02
JP2002530353A (ja) 2002-09-17
CA2351470A1 (en) 2000-06-02
BR9915460A (pt) 2001-07-17
IL142220A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
ATE235915T1 (de) Behandlung von hämorrhagischem virusfieber mit protein c
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
ATE364386T1 (de) (s,s)-reboxetine zur behandlung von chronischen erschöpfungssyndrom
DE69925256D1 (de) Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen
ATE234092T1 (de) 2-alkylpyrrolidine
BG102644A (bg) Подобрени концентрирани инжекционни и инфузионниразтвори за интравазално прилагане
ES2191292T3 (es) Compuestos antivirales poliaromaticos.
ATE252830T1 (de) Neue psoralene zur inaktivierung von pathogenen
BG100930A (bg) Фармацевтични състави и лекарствени средства за профилактика и лечение на ендотелиални нарушения
ATE218857T1 (de) Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen
ES2079068T3 (es) 2-amino-6-fenil-4h-piran-4-onas antiateroscleroticas y antitromboticas.
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
DE69110713D1 (de) 7-Oxabicycloheptan-imidazol-prostaglandin-Analoge, verwendbar bei der Behandlung von thrombotischen und vasospastischen Erkrankungen.
ES2113910T3 (es) Procedimiento para la preparacion de un concentrado de trombina asegurado contra virus.
DE69309790D1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-Furyl)-3-Derivate und pharmazeutische Präparate davon, zur Behandlung von Kardiovaskulär-Erkrankungen
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
ATE129895T1 (de) Behandlung von pulmonarer disfunktion mit 15-keto-prostaglandin-derivaten.
DE69905489D1 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
BR9915317A (pt) Método de tratar trombocitopenia induzida por heparina
DK0952982T3 (da) Hidtil ukendte hepatitis B inhibitorer
DE3378979D1 (en) 1-acyl-3-pyridylmethylguanidines and their use as antihypertensive agents
DE69916493D1 (de) Verwendung von protein c zur behandlung von thrombozytopenischer purpura und hämolytisches urämisches syndrom
ES2061775T3 (es) Derivados de estrobirulina, su obtencion y empleo.
SE9404438D0 (sv) New process
FI954110A7 (fi) Menetelmä (1R,2R)-N-metyyli-2-(3-pyridyyli)-2-tetrahydrotiopyrankarbot iamodi-1-oksidin valmistamiseksi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties